CAMBRIDGE, Mass.--(BUSINESS WIRE)--Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of data in two poster presentations at the 22nd EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics,” held in Berlin, Germany, November 16-19. One presentation is titled “Anti-Tumor Activity of CU-201, an Inhibitor of HDAC, SFK and Abl Kinases” and was presented by Rudi Bao, M.D., Ph.D., Curis’ Senior Director of Oncology on November 17th. The other presentation is titled “The First-in-Human, First-in-Class Study of CUDC-101, a Multi-Targeted Inhibitor of HDAC, EGFR and HER2: A Phase I Study in Patients with Advanced Cancer” and was presented by Toshio Shimizu, M.D., Ph. D., Visiting Clinical Fellow, South Texas Accelerated Research Therapeutics (START) on November 18th.
